Amyloid β protein (Aβ) is the main component of neuritic plaques in Alzheimer's disease
(AD), and its accumulation has been considered as the molecular driver of Alzheimer's …

Alzheimer's disease (AD) is the most prevalent neurodegenerative disease in ageing,
affecting around 46 million people worldwide but few treatments are currently available. The …

Background The accumulation of soluble and insoluble aggregated amyloid-beta (Aβ) may
initiate or potentiate pathologic processes in Alzheimer's disease. Lecanemab, a humanized …

Importance Phosphorylated tau (p-tau) is a specific blood biomarker for Alzheimer disease
(AD) pathology, with p-tau217 considered to have the most utility. However, availability of p …

Alzheimer's disease (AD), is a progressive neurodegenerative disease that affects behavior,
thinking, learning, and memory in elderly individuals. AD occurs in two forms, early onset …

The formation of amyloid fibrils is a general class of protein self-assembly behaviour, which
is associated with both functional biology and the development of a number of disorders …

Two anti-amyloid monoclonal antibodies (MABs)—lecanemab (Leqembi®) and
aducanumab (Aduhelm®)—have been approved in the USA for the treatment of Alzheimer's …

Although stem cell-based therapy has demonstrated considerable potential to manage
certain diseases more successfully than conventional surgery, it nevertheless comes with …

Mitochondrial dysfunctions are central players in Alzheimer's disease (AD). In addition,
impairments in mitophagy, the process of selective mitochondrial degradation by autophagy …

The key pathological hallmarks—extracellular plaques and intracellular neurofibrillary
tangles (NFT)—described by Alois Alzheimer in his seminal 1907 article are still central to …